Paul Heal

Paul Heal started their work experience in 2000 as a Laboratory Technician at LGC Limited. Paul then moved on to Aptuit in 2001 and eventually transitioned to Covance Laboratories in 2006. At Covance, they worked as a Toxicology Study Director until 2017 when they became the VP of Preclinical Development at Orchard Therapeutics. Throughout their roles, Paul specialized in General Toxicology, Biodistribution Studies, and Viral Vector Testing, maintaining their competence by reviewing literature, attending courses, and networking with others in the field. Paul was also involved in direct liaisons with sponsors on a global scale and responsible for developing study programs tailored to specific regulatory requirements.

Paul Heal completed their Bachelor of Science in Pharmacology at the University of Sunderland from 1992 to 1996. Following this, they pursued a Master of Science in Neuroscience at The University of Manchester from 1997 to 1998.